News

11/08

CANC to participate in clinical trial of new migrane drug

GlaxoSmithKline, Inc. has invited Child and Adolescent Neurology Consultants to participate in clinical drug trials for an investigational drug to treat migraine in adolescents aged 12 to 17. The drug combines Sumatriptan, the active ingredient in Imitrex, a time-tested and highly effective medication, and naproxen sodium. The study drug was designed to attempt to improve the efficacy of Imitrex, and received FDA approval for use in adults in May of 2008.

CANC staff members have undergone extensive training in order to be certified as a clinical test site. We are actively screening prospective participants in the study.

10/08

Austism in infants: Dr. Asaiskar interviewed by Parent’s Monthly magazine

Recognizing the symptoms of autism as early as possible is critical to a child’s outcome, says a local specialist who cares for pediatric patients.

“Most symptoms of autism occur within the first or second year of life,” says Dr. Shailesh M. Asaikar of Sacramento’s Child and Adolescent Neurology Consultants. “Yet the diagnosis is delayed until the child is ready to enter school. This disparity between the onset of symptoms and recognizing the disorder is discouraging.”

Autism is a collection of developmental aberrations with a varying severity of signs and symptoms and is therefore classified as a “spectrum disorder.” The deficits are in the areas of communication, cognition and constitution.   Read full article